Would you recommend initiating a SGLT2i for proteinuria secondary to bevacizumab in a patient who has a sub-optimal response to an ACEi or ARB?  

Obviously, SGLT2i were not studied in this setting. If the patient otherwise meets the criteria for approved uses of SGLT2i then it is reasonable to consider. The prescriber should make a careful assessment of the risk and risk factors for infections and monitor the Cr closely. An initial increase i...

We don't have specific data for this scenario, but there is no reason to think that SGLT2i would not have a beneficial role though I agree with Dr. @Latcha that risk/benefit needs to be weighed. At the same time, in this particular scenario, I'd carefully look at the time course of proteinuria, peak...